Are there any scenarios in which you would offer SBRT as your preferred treatment approach for appropriate candidates with intermediate risk prostate cancer?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Plenary Session Presentation "Primary Results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer" by Dr. Rodney Ellis.
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · University of Miami Miller School of Medicine
Answered on
Based upon the PACE-B trial, 40 Gray to the prostate, 36.25 to the PTV, which was compared to standard or moderately hypofractionated radiation, and documented non-inferiority. It is reasonable to consider stereotactic radiation therapy as a standard of care for intermediate-risk prostate cancer. If...
Join for free or sign in to see the full answer
Mednet Member
Radiation Oncology · Steward Medical Group
Answered on
Patients with small prostates, disease confined to the prostate on MRI (early-stage), and those who travel a long distance would be favorable candidates.
Join for free or sign in to see the full answer